Citadel Advisors
RXRX icon

Citadel Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Citadel Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$472K Sell
128,478
-496,181
-79% -$1.65M ﹤0.01% 9999
2026
Q1 		$1.92M Sell
624,659
-3,605,340
-85% -$13.9M ﹤0.01% 6142
2025
Q4 		$17.3M Buy
4,229,999
+2,881,315
+214% +$14.3M ﹤0.01% 2529
2025
Q3 		$6.58M Buy
1,348,684
+34,132
+3% +$179K ﹤0.01% 3883
2025
Q2 		$6.65M Sell
1,314,552
-1,341,159
-51% -$6.59M ﹤0.01% 3636
2025
Q1 		$14M Sell
2,655,711
-83,536
-3% -$609K ﹤0.01% 2438
2024
Q4 		$18.5M Buy
2,739,247
+2,505,024
+1,070% +$16.8M ﹤0.01% 2238
2024
Q3 		$1.54M Sell
234,223
-510,856
-69% -$3.66M ﹤0.01% 6000
2024
Q2 		$5.59M Buy
745,079
+404,705
+119% +$3.53M ﹤0.01% 3578
2024
Q1 		$3.39M Buy
340,374
+303,880
+833% +$3.38M ﹤0.01% 4577
2023
Q4 		$360K Sell
36,494
-266,596
-88% -$1.9M ﹤0.01% 8781
2023
Q3 		$2.32M Sell
303,090
-434,668
-59% -$4.34M ﹤0.01% 4954
2023
Q2 		$5.51M Buy
737,758
+132,243
+22% +$925K ﹤0.01% 3503
2023
Q1 		$4.04M Sell
605,515
-165,635
-21% -$1.31M ﹤0.01% 4144
2022
Q4 		$5.95M Buy
771,150
+269,280
+54% +$2.64M ﹤0.01% 3579
2022
Q3 		$5.34M Buy
501,870
+194,498
+63% +$1.97M ﹤0.01% 3755
2022
Q2 		$2.5M Sell
307,372
-602,598
-66% -$4.03M ﹤0.01% 5104
2022
Q1 		$6.51M Buy
909,970
+710,363
+356% +$7.55M ﹤0.01% 3671
2021
Q4 		$3.42M Buy
+199,607
New +$3.76M ﹤0.01% 5085

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's RXRX Position: Q2 2026 in Review

Citadel Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 79% in Q2 2026, selling an estimated $1.65M and leaving 128,478 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #9999.

Citadel Advisors first reported a position in RXRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $18.5M in Q4 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Citadel Advisors held 128,478 shares of Recursion Pharmaceuticals worth $472K as of Q2 2026.
  • Citadel Advisors sold 496,181 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #9999 holding.
  • Citadel Advisors first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • Citadel Advisors's Recursion Pharmaceuticals position peaked at $18.5M in Q4 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.